Estrogen Receptor–Positive Breast Cancer ER-positive, HER2-negative breast cancer,
which accounts for about 70% of all breast cancers, is heterogeneous. Antiestrogen therapy …

Purpose To develop evidence-based guidelines, based on a systematic review, for
endocrine therapy for postmenopausal women with hormone receptor–positive breast …

Purpose To update the ASCO clinical practice guideline on adjuvant endocrine therapy
based on emerging data about the optimal duration of aromatase inhibitor (AI) treatment …

Purpose We recently reported that the mRNA-based, 21-gene Genomic Health recurrence
score (GHI-RS) provided additional prognostic information regarding distant recurrence …

Purpose TAnDEM is the first randomized phase III study to combine a hormonal agent and
trastuzumab without chemotherapy as treatment for human epidermal growth factor receptor …

Abstract The 10 th St Gallen (Switzerland) expert consensus meeting in March 2007 refined
and extended a target-oriented approach to adjuvant systemic therapy of early breast …

Background Postmenopausal women with hormone receptor-positive early breast cancer
have persistent, long-term risk of breast-cancer recurrence and death. Therefore, trials …

Breast cancer evolution and tumor progression are governed by the complex interactions
between steroid receptor [estrogen receptor (ER) and progesterone receptor] and growth …

Background The aromatase inhibitor letrozole, as compared with tamoxifen, improves
disease-free survival among postmenopausal women with receptor-positive early breast …

Purpose To determine the relationship between quantitative estrogen-receptor (ER) and
progesterone-receptor (PgR) expression and human epidermal growth factor 2 (HER-2) …